Cholinesterase inhibitors stabilize Alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 920, Issue , 2000, Pages 321-327

  Giacobini, Ezio ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; HEPTYLSTIGMINE TARTRATE; METRIFONATE; PHYSOSTIGMINE; PLACEBO; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; MAJOR CLINICAL STUDY; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0034535351     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06942.x     Document Type: Conference Paper

References (32)

1. Controlled trial of tacrine in Alzheimer's disease
2. 30 week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
3. Clinical trials and therapeutics: Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease
4. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease
5. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
6. A 24 week, double blind placebo controlled trial of donepezil in patients with AD
7. Treatment of Alzheimer's disease
8. The effects of donepezil in Alzheimer's Disease - Results from a multinational trial
9. An overview of the development of SDZ ENA 713, a brain selective cholinesterase inhibitor disease
10. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial
11. Rivastigmine. A review of its use in Alzheimer's Disease
12. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor for Alzheimer disease
13. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
14. The effects of Metrifonate on the cognitive, behavioral and functional performance of Alzheimer's disease patients
15. Metrifonate improves the cognitive deficits of Alzheimer's disease patients in a dose-related manner
16. Galanthamine hydrobromide - Results of a group study
17. Methanesulphonyl fluoride (MSF)
18. Randomized trial of controlled release physostigmine
19. Cholinesterase inhibitors for Alzheimer's disease therapy, from tacrine to future applications
20. Cholinesterase inhibitors increase secretion of APPs in barin cortex
21. Cholinesterase inhibitors do more than inhibit cholinesterase
22. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme
23. Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid percursor protein (APP)
24. The beta-amyloid protein influence on acethyl-cholinesterase expression, assembly and glycosylation
25. Amyloid-beta peptide induces cyclooxygenase-2 expression and activity in brain-derived cells
26. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease
27. Long-term tacrine treatment slows the increase of theta power in the EEG of mild Alzheimer patients compared to untreated controls
28. Long-term treatment with rivastigmine continue to provide benefits for up to one year
29. Long-term cognitive benefit from galanthamine in Alzheimer's disease
30. Donepezil enhances global function, cognition and activities of daily living compared with placebo one year
31. Donepezil preserves functional status in Alzheimer's disease patients